MCID: PNC041
MIFTS: 64

Pancreatic Ductal Adenocarcinoma malady

Categories: Endocrine diseases, Cancer diseases

Aliases & Classifications for Pancreatic Ductal Adenocarcinoma

About this section

Aliases & Descriptions for Pancreatic Ductal Adenocarcinoma:

Name: Pancreatic Ductal Adenocarcinoma 35 11 13 68
 
Ductal Adenocarcinoma of the Pancreas 11

Classifications:



External Ids:

Disease Ontology11 DOID:3498
NCIt45 C9120

Summaries for Pancreatic Ductal Adenocarcinoma

About this section
Disease Ontology:11 A pancreatic adenocarcinoma that derives from pancreatic duct cells.

MalaCards based summary: Pancreatic Ductal Adenocarcinoma, also known as ductal adenocarcinoma of the pancreas, is related to pancreatitis and adenocarcinoma, and has symptoms including abdominal pain, icterus and pruritus. An important gene associated with Pancreatic Ductal Adenocarcinoma is KRAS (KRAS Proto-Oncogene, GTPase), and among its related pathways are Mitophagy - animal and PI3K-AKT-mTOR signaling pathway and therapeutic opportunities. Affiliated tissues include pancreas, lymph node and liver, and related mouse phenotypes are Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance and Decreased cell migration.

Related Diseases for Pancreatic Ductal Adenocarcinoma

About this section

Diseases related to Pancreatic Ductal Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 181)
idRelated DiseaseScoreTop Affiliating Genes
1pancreatitis11.2
2adenocarcinoma11.2
3mitochondrial neurogastrointestinal encephalopathy disease10.4KRAS, SMAD4, TP53
4pineal region mature teratoma10.4EGFR, ERBB2
5exudative glomerulonephritis10.4EGFR, KRAS, TP53
6clear cell adenofibroma10.4CDKN2A, TP53
7oro-mandibular-limb hypogenesis syndrome10.4CDKN2A, ERBB2, TP53
8linitis plastica10.4CDH1, TP53
9acquired hemangioma10.3CDKN2A, ERBB2, TP53
10intermediate malignant teratoma10.3CDKN2A, EGFR, KRAS
11familial hypopituitarism10.3CDH1, SMAD4, TP53
12chronic monocytic leukemia10.3CDKN2A, EGFR, TP53
13urethral villous adenoma10.3CDKN2A, EGFR, PROM1
14thymus squamous cell carcinoma10.3CDKN2A, EGFR, TP53
15secondary hyperparathyroidism of renal origin10.3CDKN2A, EGFR, TP53
16breast ductal carcinoma10.3CTNNB1, KRAS, TP53
17endometrial squamous cell carcinoma10.3AKT1, CDKN2A, TP53
18wolffian adnexal neoplasm10.3EGFR, TP53
19basaloid squamous cell carcinoma10.3CDH1, EGFR, ERBB2
20skeletal tuberculosis10.3CDKN2A, ERBB2
21adult syndrome10.3CTNNB1, KRAS, TP53
22lacrimal gland adenoid cystic carcinoma10.3CDKN2A, TP53
23immunodeficiency due to a late component of complement deficiency10.3EGFR, ERBB2, TP53
24his bundle tachycardia10.3EGFR, ERBB2, TP53
25combined t cell and b cell immunodeficiency10.3CDH1, EGFR, ERBB2
26tamoxifen-related endometrial lesion10.3CDKN2A, ERBB2, KRAS, TP53
27gastric cancer, somatic10.3CDH1, ERBB2, KRAS
28pityriasis rosea10.3CDKN2A, EGFR, TP53
29retinal disease10.3CDH1, EGFR, ERBB2
30submucosal invasive colon adenocarcinoma10.3CTNNB1, SMAD4, TP53
31severe pre-eclampsia10.3EGFR, HRAS, KRAS
32interstitial lung disease10.3CDKN2A, EGFR, TP53
33malignant skin fibrous histiocytoma10.3HRAS, KRAS
34bile duct disease10.3EGFR, HRAS, KRAS
35multicentric papillary thyroid carcinoma10.3CTNNB1, EGFR, TP53
36spondylarthropathy10.3CDKN2A, HRAS, TP53
37uterine corpus endometrial stromal sarcoma10.3HRAS, KRAS, TP53
38pancreatic cancer10.3
39kidney clear cell sarcoma10.3EGFR, HRAS, KRAS
40vaginal endometrial stromal sarcoma10.3AKT1, CDKN2A, MSLN
41bilateral hypoactive labyrinth10.3HRAS, KRAS, SMAD4
42cervical lymphoepithelioma-like carcinoma10.3EGFR, ERBB2, MUC1
43fallopian tube adenocarcinoma10.3CDKN2A, ERBB2, TP53
44plasmacytoma10.3HRAS, KRAS, TP53
45gallbladder pleomorphic giant cell adenocarcinoma10.3CDKN2A, HRAS, TP53
46adult epithelioid sarcoma10.3CDKN2A, HRAS, TP53
47striated muscle rhabdoid tumor10.3CDKN2A, HRAS, KRAS
48reactive arthritis10.3CTNNB1, EGFR, ERBB2, TP53
49immunodeficiency due to a classical component pathway complement deficiency10.3CDKN2A, EGFR, MUC1
50dysembryoplastic neuroepithelial tumor10.3CDH1, EGFR, ERBB2, TP53

Graphical network of the top 20 diseases related to Pancreatic Ductal Adenocarcinoma:



Diseases related to pancreatic ductal adenocarcinoma

Symptoms & Phenotypes for Pancreatic Ductal Adenocarcinoma

About this section

UMLS symptoms related to Pancreatic Ductal Adenocarcinoma:


abdominal pain, icterus, pruritus

GenomeRNAi Phenotypes related to Pancreatic Ductal Adenocarcinoma according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00210-A9.9CTNNB1, EGFR, ERBB2, HRAS, MUC1
2GR00055-A-19.9AKT1, CTNNB1, EGFR, HRAS, KRAS, MUC1
3GR00381-A-19.3AKT1, CDH1, CDKN2A, EGFR, HRAS, KRAS

MGI Mouse Phenotypes related to Pancreatic Ductal Adenocarcinoma according to GeneCards Suite gene sharing:

41 (show all 23)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00011869.9CDKN2A, CTNNB1, EGFR, KRAS, PROM1, TP53
2MP:00053679.6CTNNB1, EGFR, GLI1, HRAS, KRAS, SMAD4
3MP:00053829.4CTNNB1, EGFR, ERBB2, GLI1, HRAS, KRAS
4MP:00053699.3AKT1, CDKN2A, CTNNB1, EGFR, ERBB2, KRAS
5MP:00053719.0CTNNB1, EGFR, ERBB2, GLI1, KRAS, PTF1A
6MP:00053709.0AKT1, CDKN2A, CTNNB1, EGFR, KRAS, PTF1A
7MP:00053808.9AKT1, CDH1, CDKN2A, CTNNB1, EGFR, ERBB2
8MP:00053898.8AKT1, CDH1, CDKN2A, CTNNB1, EGFR, ERBB2
9MP:00053908.8AKT1, CDKN2A, CTNNB1, EGFR, ERBB2, HRAS
10MP:00053888.8AKT1, CDKN2A, CTNNB1, EGFR, ERBB2, GLI1
11MP:00107718.8AKT1, CDH1, CDKN2A, CTNNB1, EGFR, ERBB2
12MP:00053818.7CDH1, CDKN2A, CTNNB1, EGFR, ERBB2, GLI1
13MP:00020068.6AKT1, CDH1, CDKN2A, CTNNB1, EGFR, ERBB2
14MP:00053858.5AKT1, CDH1, CDKN2A, CTNNB1, EGFR, ERBB2
15MP:00030128.4CDH1, CDKN2A, CTNNB1, EGFR, GLI1, HRAS
16MP:00107688.4AKT1, CDH1, CDKN2A, CTNNB1, EGFR, ERBB2
17MP:00053868.3AKT1, CDKN2A, CTNNB1, ERBB2, GLI1, HRAS
18MP:00028738.2AKT1, CDH1, CTNNB1, EGFR, ERBB2, GLI1
19MP:00053848.2AKT1, CDH1, CDKN2A, CTNNB1, EGFR, ERBB2
20MP:00053788.1AKT1, CDH1, CDKN2A, CTNNB1, EGFR, ERBB2
21MP:00053768.1AKT1, CDH1, CDKN2A, CTNNB1, EGFR, ERBB2
22MP:00053798.1AKT1, CDH1, CDKN2A, CTNNB1, EGFR, ERBB2
23MP:00036317.8AKT1, CDKN2A, CTNNB1, EGFR, ERBB2, GLI1

Drugs & Therapeutics for Pancreatic Ductal Adenocarcinoma

About this section

Drugs for Pancreatic Ductal Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 151)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
FluorouracilapprovedPhase 3, Phase 2, Phase 1185651-21-83385
Synonyms:
1-fluoro-1h-pyrimidine-2,4-dione
1004-03-1
1upf
2,4-Dihydroxy-5-fluoropyrimidine
2,4-Dioxo-5-fluoropryimidine
2,4-Dioxo-5-fluoropyrimidine
47576_FLUKA
4921-97-5
5 FU Lederle
5 FU medac
5 Fluorouracil
5 Fluorouracil biosyn
5 HU Hexal
5-FU
5-FU (TN)
5-FU Lederle
5-FU medac
5-Faracil
5-Fluor-2,4(1H,3H)-pyrimidindion
5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]
5-Fluor-2,4-dihydroxypyrimidin
5-Fluor-2,4-dihydroxypyrimidin [Czech]
5-Fluor-2,4-pyrimidindiol
5-Fluor-2,4-pyrimidindiol [Czech]
5-Fluoracil
5-Fluoracil [German]
5-Fluoracyl
5-Fluoro-2,4(1H,3H)-pyrimidinedione
5-Fluoro-2,4-pyrimidinedione
5-Fluoropyrimidin-2,4-diol
5-Fluoropyrimidine-2,4-dione
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluoruracil
5-Fluoruracil [German]
5-Fluracil
5-Ftouracyl
5-HU Hexal
5-fluoro uracil
5-fluoro-1H-pyrimidine-2,4-dione
5-fluoropyrimidine-2,4(1H,3H)-dione
5-fluorouracil
51-21-8
5FU
79108-01-3
AC-11201
AC1L1FTE
AC1Q4N2X
AI3-25297
AKOS000119162
AKOS003237897
AccuSite
Actino-Hermal
Adrucil
Adrucil (TN)
Allergan Brand of Fluorouracil
Arumel
BB_NC-0576
BSPBio_002048
C07649
C4H3FN2O2
CCRIS 2582
CHEBI:46345
CHEMBL185
CID3385
CPD0-1327
CPD000038082
CSP Brand of Fluorouracil
Carac
Carac (TN)
Carzonal
Cinco FU
Cytosafe
D005472
D00584
DB00544
Dakota Brand of Fluorouracil
Dakota, Fluorouracile
Dermatech Brand of Fluorouracil
Dermik Brand of Fluorouracil
DivK1c_000054
EINECS 200-085-6
EU-0100536
Effluderm
Effluderm (free base)
Efudex
Efudix
Efurix
F 6627
F0151
F6627_SIGMA
F8423_SIGMA
FT-0082524
FU
Ferrer Brand of Fluorouracil
Fiverocil
Fluoro Uracil
Fluoro Uracile ICN
Fluoro-Uracile ICN
Fluoro-uracile
Fluoro-uracilo
Fluoroblastin
Fluoroplex
Fluoroplex (TN)
Fluorouracil
Fluorouracil (JP15/USP/INN)
Fluorouracil GRY
Fluorouracil Mononitrate
Fluorouracil Monopotassium Salt
Fluorouracil Monosodium Salt
Fluorouracil Potassium Salt
Fluorouracil Teva Brand
Fluorouracil [USAN:INN:BAN:JAN]
 
Fluorouracil-GRY
Fluorouracile
Fluorouracile Dakota
Fluorouracile [DCIT]
Fluorouracilo
Fluorouracilo Ferrer Far
Fluorouracilo [INN-Spanish]
Fluorouracilum
Fluorouracilum [INN-Latin]
Fluoruracil
Fluouracil
Flurablastin
Fluracedyl
Fluracil
Fluracilum
Fluri
Fluril
Fluro Uracil
Fluroblastin
Flurodex
Flurouracil
Flurox
Ftoruracil
Gry Brand of Fluorouracil
HMS1920O18
HMS2090I04
HMS2091F19
HMS500C16
HSDB 3228
Haemato Brand of Fluorouracil
Haemato fu
Haemato-fu
Hexal Brand of Fluorouracil
I07-0022
ICN Brand of Fluorouracil
IDI1_000054
IN1335
KBio1_000054
KBio2_001321
KBio2_003889
KBio2_006457
KBio3_001268
KBioGR_001253
KBioSS_001321
Kecimeton
LS-153
Lopac-F-6627
Lopac0_000536
MLS000069498
MLS002415705
MolPort-000-156-102
MolPort-003-990-447
MolPort-004-758-143
MolPort-004-758-144
MolPort-005-861-486
NCGC00015442-01
NCGC00015442-03
NCGC00015442-10
NCGC00091349-01
NCGC00091349-02
NCGC00091349-03
NCGC00091349-04
NCGC00091349-05
NCGC00091349-07
NCGC00091349-08
NCI60_001652
NINDS_000054
NSC 19893
NSC-19893
NSC19893
Neocorp Brand of Fluorouracil
Neofluor
Onkofluor
Onkoworks Brand of Fluorouracil
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
Riemser Brand of Fluorouracil
Ro 2-9757
Ro-2-9757
Roche Brand of Fluorouracil
S1209_Selleck
SAM002264615
SMR000038082
SPBio_000291
SPECTRUM1500305
STK297802
Spectrum2_000076
Spectrum3_000434
Spectrum4_000557
Spectrum5_000718
Spectrum_000841
T5233394
TL8006093
Teva Brand of Fluorouracil
Timazin
U 8953
U-8953
UNII-U3P01618RT
UPCMLD-DP130
UPCMLD-DP130:001
URF
Ulup
WLN: T6MVMVJ EF
ZINC00897110
biosyn Brand of Fluorouracil
fluorouracil
inhibits thymilidate synthetase
medac Brand of Fluorouracil
nchembio.90-comp3
nchembio809-comp6
ribosepharm Brand of Fluorouracil
tetratogen
2
Paclitaxelapproved, vet_approvedPhase 3, Phase 1, Phase 2, Early Phase 1286433069-62-436314
Synonyms:
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-Epi-Paclitaxel
7-Epi-Taxol
7-Epipaclitaxel
7-Epitaxol
7-epi-Paclitaxel
7-epi-Taxol
AB00513812
ABI 007
ABI-007
ABI007
AC-675
AC1L1IOG
AC1L1VJI
AC1L9AVF
ACon1_002231
ANX-513
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
Ambotz33069-62-4
Anzatax
Asotax
BIDD:PXR0046
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
BSPBio_000290
BSPBio_001152
BSPBio_002614
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
Bristaxol
C07394
C466458
C47H51NO14
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
CPD-8718
Capxol
D00491
DB01229
DHP-107
DHP-208
DRG-0190
DTS-301
DivK1c_000441
EU-0101201
Ebetaxel
EmPAC
Epitaxol
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
KBioGR_000492
KBioGR_001893
 
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LMPR0104390001
LS-31070
LipoPac
Lopac0_001201
MBT 0206
MEGxp0_001940
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MPI-5018
Micellar Paclitaxel
Mitotax
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
NCI60_000601
NINDS_000441
NK 105
NP-010981
NSC 125973
NSC-125973
NSC125973
NSC358882
Nanotaxel
Neuro_000060
Nova-12005
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S-8184 Paclitaxel Injectable Emulsion
S1150_Selleck
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
SPECTRUM1503908
ST50306996
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
Spectrum_001536
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TAXOL (TN)
TAXOL, 10-EPI,
TXL
TaxAlbin
Taxol
Taxol A
Taxol Konzentrat
Taxol.RTM. (Registered Trademark)
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
Xorane
Yewtaxan
abi-007
albumin-bound paclitaxel
cMAP_000068
nab-paclitaxel
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
paclitaxel
weekly paclitaxel
3
PancrelipaseapprovedPhase 3, Phase 1, Phase 2, Early Phase 197053608-75-6
Synonyms:
1,4-alpha-D- glucan glucanohydrolase
PA
 
Pancreatic alpha-amylase precursor
Pancrelipase (amylase
lipase
protease)
4
Capecitabineapproved, investigationalPhase 3, Phase 2, Phase 11342154361-50-960953
Synonyms:
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
154361-50-9
158798-73-3
5'-Deoxy-5-fluoro-N-((pentyloxy)carbonyl)cytidine
5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine
AC1L1U83
AC1Q4KU8
Ambap154361-50-9
C110904
C12650
C15H22FN3O6
CAPE
CAPECITABINE
CHEBI:31348
CHEMBL1773
CID60953
Capecitabin
Capecitabina
Capecitabine (JAN/USAN/INN)
Capecitabine [USAN]
Capecitabinum
Capecitibine
Capiibine
Carbamic acid, (1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-, pentyl ester
Caxeta
 
D01223
DB01101
FT-0082472
HSDB 7656
LS-59070
MolPort-005-938-254
N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
R-340
R340
RG-340
Ro 09-1978
Ro 09-1978/000
Ro-09-1978
Ro-09-1978/000
S1156_Selleck
UNII-6804DJ8Z9U
Xabine
Xeloda
Xeloda (TN)
Xeloda, Captabin, Capecitabine
ZINC03806413
capecitabina
capecitabine
capecitabinum
pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate
5
GemcitabineapprovedPhase 3, Phase 1, Phase 2, Early Phase 1201895058-81-460750
Synonyms:
103882-84-4
122111-03-9
2',2'-DiF-dC
2',2'-Difluoro-2'-deoxycytidine
2',2'-Difluorodeoxycytidine
2'-Deoxy-.beta.-D-2',2'-difluorocytidine
2'-Deoxy-2',2'-difluorocytidine
4-Amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
4-Amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl]-1H-pyrimidin-2-one
4-amino-1-((2R,4R,5R)-3,3-Difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
95058-81-4
AB1004842
AC1L1TUQ
C07650
CCRIS 8984
CHEBI:175901
CHEMBL888
CID60750
Cytidine, 2'-deoxy-2',2'-difluoro-2'-Deoxy-.beta.-D-2',2'-difluorocytidine
D02368
DB00441
DDFC
DFDC
DFdC
DFdCyd
Folfugem
GEO
Gamcitabine
GemLip
Gemcel
 
Gemcin
Gemcitabin
Gemcitabina
Gemcitabina [INN-Spanish]
Gemcitabine
Gemcitabine (USAN/INN)
Gemcitabine HCl
Gemcitabine hydrochloride
Gemcitabine stereoisomer
Gemcitabinum
Gemcitabinum [INN-Latin]
Gemtro
Gemzar
Gemzar (hydrochloride)
HMS2089P10
HSDB 7567
Inno-D07001
LS-59139
LY 188011
LY-188011
LY188011
NCGC00168784-01
NChemBio.2007.10-comp25
NSC 613327
NSC613327
TL8005979
UNII-B76N6SBZ8R
ZINC18279854
Zefei
gemcitabine
nchembio.573-comp7
nchembio.90-comp2
6
Irinotecanapproved, investigationalPhase 3, Phase 2, Phase 1112397682-44-5, 100286-90-660838
Synonyms:
(+)-Irinotecan
(4S)-4,11-DIETHYL-4-HYDROXY-3,14-DIOXO-3,4,12,14-TETRAHYDRO-1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL 1,4'-BIPIPERIDINE-1'-CARBOXYLATE
(4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-4,12-dihydro-1H-pyrano[3,4-f]quinolino[2,3-a]indolizin-9-yl 4-piperidylpiperidinecarboxylate
1u65
97682-44-5
AC-7469
AC1L1U0Z
AC1Q6PGI
BRD-K08547377-003-02-4
BSPBio_002346
Bio-0054
Biotecan
Biotecan (TN)
C16641
C33H38N4O6
CHEBI:105985
CHEMBL481
CID60838
CP0
Campothecin-11
Campto
Camptosar
 
Camptosar, Campto, CPT-11, Irinotecan
Camptothecin-11
D08086
DB00762
FT-0083650
HSDB 7607
IRINOTECAN HYDROCHLORIDE Trihydrate
IRINOTECAN, CPT-11
Irinotecan (INN)
Irinotecan Hcl
Irinotecan Hydrochloride
Irinotecan Hydrochloride Trihydrate
Irinotecan [INN:BAN]
Irinotecan hydrochloride
Irinotecanum
Irinotecanum [INN-Latin]
LS-44589
NCI60_005051
NSC728073
S1198_Selleck
TL8006026
UNII-7673326042
irinotecan
7
Oxaliplatinapproved, investigationalPhase 3, Phase 2, Phase 1146061825-94-35310940, 9887054, 6857599, 9887054, 43805
Synonyms:
CHEMBL1201055
CID9887054
D01790
DACPLAT
Diaminocyclohexane Oxalatoplatinum
Eloxatin
Eloxatin (TN)
Elplat
Foloxatine
L-OHP
Oxalatoplatin
 
Oxalatoplatinum
Oxaliplatin (JAN/USAN/INN)
Oxaliplatin [Usan:Inn:Ban]
Oxaliplatino [Spanish]
Oxaliplatinum [Latin]
Oxaloplatine [French]
Oxaloplatino [Spanish]
Transplatin
oxaliplatin
oxaliplatine
oxaliplatino
oxaliplatinum
8
Axitinibapproved, investigationalPhase 3109319460-85-06450551
Synonyms:
319460-85-0
790713-39-2
AC-1539
AC1O51X3
AG 013736
AG-013736
AG-013736, Axitinib
AG-13736
AG013736
Axitinib
C503983
CID6450551
 
EC-000.2322
I14-1971
INLYTA
Inlyta
MolPort-006-392-413
N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide
N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide
S1005_Selleck
ST51054130
UNII-C9LVQ0YUXG
ZINC03816287
axitinib
axitinibum
9
Hyaluronic acidapproved, vet_approvedPhase 34699004-61-953477741, 24759
Synonyms:
Hyaluronan
Hyaluronate
Hyaluronic acid
Hylartil
Hyruan Plus
Luronit
 
Macronan
Mucoitin
Nutra-HAF
Q 5AQ
Sepracoat
Sepragel Sinus
Sofast
Synvisc
10
LevoleucovorinapprovedPhase 3, Phase 2, Phase 172868538-85-2
Synonyms:
(6S)-5-Formyl-5,6,7,8-tetrahydrofolic acid
(6S)-5-formyltetrahydrofolic acid
(6S)-Folinic acid
(6S)-Leucovorin
 
(S)-Leucovorin
Citrovorum factor
L-Folinic acid
Levofolene
Levofolinic acid
N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamic acid
11
leucovorinapproved, NutraceuticalPhase 3, Phase 2, Phase 1323558-05-954575, 6560146, 143
Synonyms:
(5-formyl-5,6,7,8-tetrahydropteroyl)glutamate
(6R,S)-5-Formyltetrahydrofolate
10-Formyl-7,8-dihydrofolate
10-Formyl-7,8-dihydrofolic acid
5-Formyl-5,6,7,8-tetrahydrofolate
5-Formyl-5,6,7,8-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid
5-Formyltetrahydrofolate
5-Formyltetrahydrofolic acid
5-Formyltetrahydropteroylglutamate
5-Formyltetrahydropteroylglutamic acid
5-formyltetrahydrofolic acid
Acide folinique
Calcium citrovorum factor
Calcium folinate
Citrovorum factor
Folinate
Folinic acid
Folinic acid calcium salt
 
Folinic acid calcium salt USP27
Folinic acid-SF
L(-)-5-Formyl-5,6,7,8-tetrahydrofolic acid
L-Leucovorin
L-N-[p-[[(2-Amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]-Glutamic acid
L-leucovorin
Leucal
Leucovorin calcium
Leucovorin folinic acid
Leucovorinum
Leukovorin
Levoleucovorin
N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid
N5-Formyl-5,6,7,8-tetrahydrofolate
N5-Formyl-5,6,7,8-tetrahydrofolic acid
N5-Formyl-THF
N5-Formyltetrahydrofolate
N5-Formyltetrahydrofolic acid
Welcovorin
Wellcovorin
folinate
12
Folic Acidapproved, nutraceutical, vet_approvedPhase 3, Phase 2, Phase 1439259-30-36037
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
AI3-26387
AKOS000503224
ARONIS014410
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
Antianemia factor
Apo-Folic
BIDD:ER0563
BIDD:GT0641
BIF0608
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
FOL
Facid
Factor U
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
Folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
Folipac
Folsaeure
 
Folsan
Folsaure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
Incafolic
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
LS-2157
Liver Lactobacillus casei factor
MLS001304016
MLS001335861
Millafol
Mission prenatal
Mittafol
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-Pteroyl-L-glutamic acid
N-[(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
NINDS_000494
NSC 3073
Nifolin
Nifolin [Denmark]
Novofolacid
Novofolacid [Canada]
PGA
PGA (VAN)
Prestwick3_000627
Prestwick_230
PteGlu
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylglutamate
Pteroylglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
SMP2_000137
SMR000471860
SPBio_001357
SPECTRUM1502020
Serum Folate Level
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
Spectrum_001381
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin B9
Vitamin Bc
Vitamin Be
Vitamin M
bmse000299
folic acid
nchembio.108-comp10
13topoisomerase I inhibitorsPhase 3, Phase 2, Phase 11370
14Topoisomerase InhibitorsPhase 3, Phase 2, Phase 15069
15pancreatinPhase 3, Phase 1, Phase 2, Early Phase 1970
16Anti-Infective AgentsPhase 3, Phase 1, Phase 2, Early Phase 122062
17Vitamin B ComplexPhase 3, Phase 2, Phase 14337
18MicronutrientsPhase 3, Phase 2, Phase 16001
19AntidotesPhase 3, Phase 21071
20Protective AgentsPhase 3, Phase 2, Phase 17443
21acivicinPhase 3, Phase 247
22AntimetabolitesPhase 3, Phase 1, Phase 2, Early Phase 112054
23Antimetabolites, AntineoplasticPhase 3, Phase 1, Phase 2, Early Phase 17361
24Immunosuppressive AgentsPhase 3, Phase 1, Phase 2, Early Phase 113086
25
Erlotinib HydrochloridePhase 3, Phase 2, Phase 1810183319-69-9176871
Synonyms:
 
erlotinib hydrochloride
26Albumin-Bound PaclitaxelPhase 3, Phase 1, Phase 2, Early Phase 12864
27VitaminsPhase 3, Phase 2, Phase 15282
28Trace ElementsPhase 3, Phase 2, Phase 16001
29Antineoplastic Agents, PhytogenicPhase 3, Phase 1, Phase 2, Early Phase 15602
30Antimitotic AgentsPhase 3, Phase 1, Phase 2, Early Phase 15657
31Antiviral AgentsPhase 3, Phase 1, Phase 2, Early Phase 19967
32Adjuvants, ImmunologicPhase 3, Phase 12554
33Liver ExtractsPhase 3, Phase 14067
34Protein Kinase InhibitorsPhase 3, Phase 1, Phase 23689
35ViscosupplementsPhase 3390
36HematinicsPhase 31684
37Vitamin B9NutraceuticalPhase 3, Phase 2, Phase 14392
38FolateNutraceuticalPhase 3, Phase 2, Phase 14392
39
CisplatinapprovedPhase 1, Phase 2277015663-27-184093, 441203, 2767
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
CDDP
CHEBI:35852
CID441203
CPD0-1392
CPDC
CPDD
Carboquone
Cis Pt II
Cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
Cismaplat
Cisplatine
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
DB00515
DDP
DDPT
Diamminedichloroplatinum
 
EU-0100918
Lederplatin
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
Trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
cis-DDP
cis-Diamminedichloroplatinum
cis-Dichlorodiammineplatinum(II)
cis-[PtCl2(NH3)2]
cis-diamminedichloridoplatinum(II)
cis-diamminedichloroplatinum(II)
nchembio773-comp1
trans-diamminedichloridoplatinum(II)
40
Doxorubicinapproved, investigationalPhase 2175123214-92-831703
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
111266-55-8
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
14-hydroxydaunomycin
14-hydroxydaunorubicine
23214-92-8
23257-17-2
24385-08-8
25311-50-6
25316-40-9
25316-40-9 (hydrochloride)
29042-30-6
AC1L1M5T
AC1Q29OJ
ADM
ADR
Adriablastin
Adriacin (hydrochloride salt)
Adriamycin
Adriamycin PFS
Adriamycin PFS (hydrochloride salt)
Adriamycin RDF
Adriamycin RDF (hydrochloride salt)
Adriamycin Semiquinone
Adriamycin semiquinone
Adriblas tina
Adriblastin
Adriblastina
Adriblastina (TN)
Adriblastina (hydrochloride salt)
Aerosolized Doxorubicin
BPBio1_000502
BRD-K92093830-003-04-3
BSPBio_000456
BSPBio_001031
C01661
C27H29NO11
CCRIS 739
CHEBI:28748
CHEMBL179
CID31703
Caelyx
Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74
Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120
D03899
DB00997
DM2
DOX-SL
Doxil
Doxo
Doxorubicin
Doxorubicin (USAN/INN)
Doxorubicin HCl
 
Doxorubicin Hydrochloride
Doxorubicin [USAN:INN:BAN]
Doxorubicin citrate
Doxorubicin hydrochloride (hydrochloride salt)
Doxorubicin-P4/D10
Doxorubicin-P4/D10 conjugate
Doxorubicin-hLL1
Doxorubicin-hLL1 conjugate
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicine
Doxorubicine [INN-French]
Doxorubicinum
Doxorubicinum [INN-Latin]
EINECS 245-495-6
FI 106
Farmablastina (hydrochloride salt)
HMS2089H06
HSDB 3070
Hydroxydaunomycin hydrochlor ide (hydrochloride salt)
Hydroxydaunomycin hydrochloride (hydrochloride salt)
Hydroxydaunorubicin
Hydroxydaunorubicin hydrochloride (hydrochloride salt)
JT9100000
LMPK13050001
LS-1029
LS-165655
MLS000759533
Myocet
NCI-C01514
NChemBio.2007.10-comp13
NDC 38242-874
NIOSH/JT9100000
NSC 123127
Prestwick0_000438
Prestwick1_000438
Prestwick2_000438
Prestwick3_000438
Probes1_000151
Probes2_000129
RDF Rubex
Resmycin
Rubex
Rubex (hydrochloride salt)
SMP1_000106
SPBio_002395
TLC D-99
ThermoDox
Triferric doxorubicin
UNII-80168379AG
adiblastine (hydrochloride salt)
adr iablatina (hydrochloride salt)
adriablastine (hydrochloride salt)
adriablatina (hydrochloride salt)
adriblatina (hydrochloride salt)
doxorubicin
nchembio809-comp5
41
Rucaparibapproved, investigationalPhase 216283173-50-29931954
Synonyms:
AG-014699
 
AG014699
PF-01367338
rucaparib
42
CarboplatinapprovedPhase 1, Phase 2205041575-94-410339178, 498142, 38904
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
Carbopaltin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Cbdca
Cyclobutane-1,1-dicarboxylate
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
DivK1c_000892
EINECS 255-446-0
EU-0100230
Ercar
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
IUPAC: Azane
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
 
JM 8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
LS-117689
Lopac-C-2538
Lopac0_000230
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
NINDS_000892
NSC 201345
NSC 241240
NSC-241240
NSC201345
NSC241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
Platinum(II), (1, 1-cyclobutanedicar
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Platinum, {diammine[1,1-cyclobut
S1215_Selleck
SPBio_000716
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
Spectrum_001529
UNII-BG3F62OND5
azanide
carboplatin
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
cyclobutane-1,1-dicarboxylic acid
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
platinum(2+)
43
Propofolapproved, investigational, vet_approvedPhase 2, Phase 110822078-54-84943
Synonyms:
2, 6-Diisopropylphenol
2,6 Diisopropylphenol
2,6-Bis(1-methylethyl)phenol
2,6-Bis(Isopropyl)-phenol
2,6-DIISOPROPYLPHENOL
2,6-Diisopropyl phenol
2,6-Diisopropylphenol
2,6-bis(1-methylethyl)-phenol
2,6-di(propan-2-yl)phenol
2078-54-8
28449-97-0
4-06-00-03435 (Beilstein Handbook Reference)
50356-15-5
AB00513968
AC-2038
AC1L1J9Y
AC1Q1OUI
AI3-26295
AM-149
Abbott Brand of Propofol
Alpha Brand of Propofol
Ampofol
Aquafol
Astra Brand of Propofol
AstraZeneca Brand of Propofol
BIDD:GT0436
BPBio1_000950
BPBio1_000969
BRD-K82255054-001-03-5
BRN 1866484
BSPBio_000862
Biomol-NT_000248
Braun Brand of Propofol
C07523
C12H18O
CAS-2078-54-8
CCRIS 9000
CHEBI:44915
CHEMBL526
CID4943
CPD-11437
CPD000059151
Curamed Brand of Propofol
D00549
D015742
D0617
D126608
D126608_ALDRICH
DB00818
DDS-04F
Diisopropylphenol
Dipravan
Diprivan
Diprivan (TN)
Diprivan Injectable emulsion
Disoprivan
Disoprofol
EINECS 218-206-6
EU-0100437
Fresenius Brand of Propofol
Fresenius Kabi Brand of Propofol
Fresofol
HMS1570L04
HMS2089O21
HMS2094E17
 
HSDB 7123
ICI 35,868
ICI 35868
ICI-35,868
ICI-35868
ICI35,868
ICI35868
InChI=1/C12H18O/c1-8(2)10-6-5-7-11(9(3)4)12(10)13/h5-9,13H,1-4H
Ivofol
Jsp004266
Juste Brand of Propofol
LS-996
Lopac-D126608
Lopac0_000437
MLS001066348
MLS001335999
MLS002454360
MolPort-001-794-517
NCGC00015389-01
NCGC00015389-02
NCGC00015389-04
NCGC00015389-09
NCGC00091538-01
NCGC00091538-02
NCGC00091538-03
NCGC00091538-04
NCGC00091538-05
NCGC00091538-06
NSC 5105
NSC5105
PFL
Parnell Brand of Propofol
Pisa Brand of Propofol
Prestwick0_000931
Prestwick1_000931
Prestwick2_000931
Prestwick3_000931
Propofol
Propofol (JAN/USAN/INN)
Propofol Abbott
Propofol Fresenius
Propofol IDD-D
Propofol MCT
Propofol Rovi
Propofol [USAN:INN:BAN]
Propofol(2,6-Diisopropylphenol)
Propofol-Lipuro
Propofolum
Propofolum [Latin]
Rapinovet
Recofol
Rovi Brand of Propofol
S01-0189
SAM002264610
SMR000059151
SPBio_003031
SPECTRUM1505022
ST50405911
Schering Brand of Propofol
UNII-YI7VU623SF
W505102_ALDRICH
ZD-0859
ZINC00968303
Zeneca Brand of Propofol
ghl.PD_Mitscher_leg0.558
nchembio.552-comp7
propofol
44
nivolumabapprovedPhase 2, Phase 1424946414-94-4
Synonyms:
BMS-936558
 
MDX-1106
ONO-4538
nivolumab
45
Coal tarapprovedPhase 1, Phase 22028007-45-2
Synonyms:
 
Coal tars
Tar, coal
46
Bevacizumabapproved, investigationalPhase 1, Phase 22020216974-75-3
Synonyms:
216974-75-3
Avastin
Avastin (TN)
Bevacizumab
Bevacizumab (genetical recombination)
 
Bevacizumab (genetical recombination) (JAN)
D06409
R-435
anti-VEGF monoclonal antibody
antiVEGF
bevacizumab
47
Cyclophosphamideapproved, investigationalPhase 1, Phase 2293550-18-0, 6055-19-22907
Synonyms:
(+-)-Cyclophosphamide
(-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
ASTA
ASTA B518
Anhydrous cyclophosphamide
Asta B 518
B 518
B-518
BRN 0011744
BSPBio_002099
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
CID2907
CP
CPA
CTX
CY
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
Clafen
Claphene
Cycloblastin
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide anhydrous
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
 
DB00531
DivK1c_000246
EINECS 200-015-4
EU-0100238
Endoxan
Endoxan R
Endoxan-Asta
Endoxana
Endoxanal
Endoxane
Enduxan
Genoxal
HMS2090A12
HSDB 3047
Hexadrin
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
LS-1302
LS-99787
Ledoxina
Lopac-C-0768
Lopac0_000238
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI-C04900
NCI60_002097
NINDS_000246
NSC 26271
NSC-26271
NSC26271
NSC273033
NSC273034
Neosar
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra Waste Number U058
Rcra waste number U058
Revimmune
S1217_Selleck
SK 20501
SPBio_001071
STK177249
STOCK2S-91217
Semdoxan
Sendoxan
Senduxan
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
Spectrum_000858
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
cyclophosphamide
48
Pemetrexedapproved, investigationalPhase 1, Phase 2636150399-23-8, 137281-23-3446556, 60843
Synonyms:
(2R)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid
(2S)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid
137281-23-3
150399-23-8
1juj
2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid
2-{4-[2-(2-AMINO-4-OXO-4,7-DIHYDRO-3H-PYRROLO[2,3-D]PYRIMIDIN-5-YL)-ETHYL]-BENZOYLAMINO}-PENTANEDIOIC ACID
AC1L1U1D
AC1L2PDW
AC1L98DY
AC1L9JT6
AC1OCF51
AC1Q5R1W
Alimta
Alimta (TN)
Bio-0078
C20H19N5O6.2Na
C20H21N5O6
CHEBI:195145
CHEBI:43746
CHEBI:474008
CHEMBL1200373
CHEMBL225072
CHEMBL59843
CID125891
CID394493
CID446556
CID60843
CID6918197
D03828
D07472
DB00642
Disodium N-(p-(2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)-L-glutamate
 
HSDB 7316
I06-1253
I06-1294
I06-2128
L-Glutamic acid, N-(4-(2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)-, disodium salt
LS-172988
LS-173384
LY 231,514
LY 231514
LY-231,514
LY-2315
LY-231514
LY231514
LY231514 disodium
LYA
N-(4-(2-(2-Amino-3,4-dihydro-4-oxo-7H-pyrrolo(2,3-d)pyrimdin-5-yl)ethyl)benzoyl)glutamic acid
NCGC00167517-01
NCI60_035021
NSC698037
Pemetrexed
Pemetrexed (INN)
Pemetrexed Disodium
Pemetrexed [INN:BAN]
Pemetrexed disodium
Pemetrexed disodium (USAN)
Pemetrexed disodium [USAN]
Rolazar
ST51053024
Tifolar
UNII-04Q9AIZ7NO
UNII-2PKU919BA9
disodium (2R)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioate
disodium (2S)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioate
n-{4-[2-(2-amino-4-oxo-4,7-dihydro-1h-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-d-glutamic acid
nchembio.108-comp6
49
PembrolizumabapprovedPhase 1, Phase 25071374853-91-4
Synonyms:
Keytruda
 
MK-3475
lambrolizumab
50
OlaparibapprovedPhase 2140763113-22-023725625
Synonyms:
4-(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorobenzyl)phthalazin-1(2H)-one
4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one
4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
763113-22-0
937799-91-2
AKOS005145764
AZD 2281
AZD-2281
AZD2281
 
Acylpiperazine analogue, 47
CHEMBL521686
EC-000.2324
EN002690
FT-0083489
KU-0059436
KU-59436
Olaparib
Olaparib, KU-0059436, AZD2281, KU0059436, AZD2281
S1060_Selleck
olaparib

Interventional clinical trials:

(show top 50)    (show all 160)
idNameStatusNCT IDPhase
1Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent ChemoradiotherapyNot yet recruitingNCT02570529Phase 4
2Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.CompletedNCT00471146Phase 3
3An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing RadiationCompletedNCT00132704Phase 3
4A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal AdenocaRecruitingNCT02715804Phase 3
5A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic AdenocarcinomaRecruitingNCT02993731Phase 3
6Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By SurgeryRecruitingNCT01013649Phase 3
7Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus mFolfirinox to Treat Resected Pancreatic AdenocarcinomaActive, not recruitingNCT01526135Phase 3
8Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal AdenocarcinomaTerminatedNCT02101021Phase 3
9Nab-Paclitaxel+Cisplatin+Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (PDA)Unknown statusNCT01893801Phase 1, Phase 2
10Modulation of the Immune Response in Patients With Pancreatic Tubular AdenocarcinomaUnknown statusNCT01021800Phase 2
11Modified FOLFIRINOX for Gemcitabine Refractory Pancreatic Cancer: A Phase II Multicenter TrialUnknown statusNCT02440958Phase 2
12Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Advanced Pancreatic CancerUnknown statusNCT02135822Phase 2
13Efficacy Study of Gemcitabine, Paclitaxel, and Irradiation in the Treatment of Pancreatic CancerUnknown statusNCT00226746Phase 2
14Chemotherapy Selection Based on Therapeutic Targets for Advanced Pancreatic CancerUnknown statusNCT01394120Phase 2
15Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic CancerCompletedNCT01580397Phase 2
16A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA MutationCompletedNCT02042378Phase 2
17Capecitabine and Oxaliplatin in Patients With Advanced or Metastatic Pancreatic AdenocarcinomaCompletedNCT00585078Phase 2
18Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With ChemotherapyCompletedNCT01658943Phase 2
19Atu027 Plus Gemcitabine in Advanced or Metastatic Pancreatic Cancer (Atu027-I-02)CompletedNCT01808638Phase 1, Phase 2
20A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic CancerCompletedNCT00902291Phase 2
21A Study of AGS-1C4D4 in Pancreatic Cancer Subjects Previously Treated in Protocol 2008002CompletedNCT01608711Phase 2
22QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal CancerCompletedNCT01040000Phase 1, Phase 2
23A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal AdenocarcinomaRecruitingNCT02981342Phase 2
24Nab-pacliatxel Plus Gemcitabine in Korean Patients With Metastatic Pancreatic Ductal AdenocarcinomaRecruitingNCT02426281Phase 2
25Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal AdenocarcinomaRecruitingNCT02754726Phase 2
26PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal AdenocarcinomaRecruitingNCT02487277Phase 2
27A Phase II Study of Neoadjuvant FOLFIRINOXRecruitingNCT02178709Phase 2
28Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid TumorsRecruitingNCT02810418Phase 1, Phase 2
29A Study of Durvalumab in Patients With BR PDA Following Neoadjuvant Therapy and Successful Surgical ResectionRecruitingNCT03038477Phase 2
30Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular CorrelatesRecruitingNCT02723331Phase 2
31Study of NAC of GA Therapy for Patients With BRPCRecruitingNCT02926183Phase 2
32Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic CancerRecruitingNCT02125136Phase 2
33Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic CancerRecruitingNCT02047513Phase 2
34Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic CancerRecruitingNCT02562898Phase 1, Phase 2
35HIPEC as Neoadjuvant Treatment for Resectable Pancreatic AdenocarcinomaRecruitingNCT02850874Phase 2
36Effect of Intratumoral Injection of Gene Therapy for Locally Advanced Pancreatic CancerRecruitingNCT02806687Phase 2
37Near-infrared Image Guided Surgery in Pancreatic AdenocarcinomaRecruitingNCT02743975Phase 1, Phase 2
38A Study of Epacadostat in Combination With a PD-1 Inhibitor and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207)RecruitingNCT03085914Phase 1, Phase 2
39Phase I/II Study of IMMU-132 in Patients With Epithelial CancersRecruitingNCT01631552Phase 1, Phase 2
40Olaparib for BRCAness Phenotype in Pancreatic CancerRecruitingNCT02677038Phase 2
41Safety and Efficacy Evaluation of iAPA-DC/CTL Combined Gemcitabine Therapy on Advanced Pancreatic CancerRecruitingNCT02529579Phase 1, Phase 2
42Parvovirus H-1 (ParvOryx) in Patients With Metastatic Inoperable Pancreatic CancerRecruitingNCT02653313Phase 1, Phase 2
43Nivolumab and Ipilimumab in Treating Patients With Rare TumorsRecruitingNCT02834013Phase 2
44Study of LOXO-101 (Larotrectinib) in Subjects With NTRK Fusion Positive Solid Tumors (NAVIGATE)RecruitingNCT02576431Phase 2
45Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal CarcinomaActive, not recruitingNCT02558894Phase 2
46Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal CarcinomaActive, not recruitingNCT02583477Phase 1, Phase 2
47Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal AdenocarcinomaActive, not recruitingNCT02289898Phase 2
48Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic PatientsActive, not recruitingNCT02732938Phase 2
49Study of Tremelimumab in Patients With Advanced Solid TumorsActive, not recruitingNCT02527434Phase 2
50Phase 2 Evaluation of Multi-modality Algorithm for Non-metastatic Adenocarcinoma of Pancreas or AmpullaActive, not recruitingNCT02626520Phase 2

Search NIH Clinical Center for Pancreatic Ductal Adenocarcinoma

Genetic Tests for Pancreatic Ductal Adenocarcinoma

About this section

Anatomical Context for Pancreatic Ductal Adenocarcinoma

About this section

MalaCards organs/tissues related to Pancreatic Ductal Adenocarcinoma:

36
Pancreas, Lymph node, Liver, T cells, Neutrophil, Breast, Adipocyte

LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Pancreatic Ductal Adenocarcinoma:
id TissueAnatomical CompartmentCell Relevance
1 PancreasPancreatic Ducts  Affected by disease

Publications for Pancreatic Ductal Adenocarcinoma

About this section

Articles related to Pancreatic Ductal Adenocarcinoma:

(show top 50)    (show all 874)
idTitleAuthorsYear
1
Adipose Triglyceride Lipase (ATGL) Expression Is Associated with Adiposity and Tumor Stromal Proliferation in Patients with Pancreatic Ductal Adenocarcinoma. (28179319)
2017
2
Overexpressions of miR-212 are associated with poor prognosis of patients with pancreatic ductal adenocarcinoma. (27814273)
2017
3
Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma. (28062705)
2017
4
Increased semaphorin 3c expression promotes tumor growth and metastasis in pancreatic ductal adenocarcinoma by activating the ERK1/2 signaling pathway. (28315433)
2017
5
DPC4 gene expression in primary pancreatic ductal adenocarcinoma: relationship with CT characteristics. (28339284)
2017
6
Cancer cell chemokines direct chemotaxis of activated stellate cells in pancreatic ductal adenocarcinoma. (28092365)
2017
7
Analysis of distinct long noncoding RNA transcriptional fingerprints in pancreatic ductal adenocarcinoma. (28220683)
2017
8
Comparison of the tumor cell secretome and patient sera for an accurate serum-based diagnosis of pancreatic ductal adenocarcinoma. (28060763)
2017
9
KRAS Mutations With No GNAS Mutations in an Intraductal Papillary Mucinous Neoplasm: Are There Common Pathways With Pancreatic Ductal Adenocarcinoma? Lessons From an Extended IPMN, Covering the Entire Pancreas. (27977634)
2017
10
DEK protein overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma. (27959420)
2017
11
Invited Commentary on "Tumor-Vessel Relationships in Pancreatic Ductal Adenocarcinoma at Multidetector CT," with Response from Dr Zaky and Colleagues. (28076018)
2017
12
MiR-181b-5p, ETS1 and c-Met pathway exacerbates the prognosis of pancreatic ductal adenocarcinoma after radiation therapy. (28064436)
2017
13
Prognostic relevance of lactate dehydrogenase in advanced pancreatic ductal adenocarcinoma patients. (28056913)
2017
14
EZH2 coupled with HOTAIR to silence MicroRNA-34a by the induction of heterochromatin formation in human pancreatic ductal adenocarcinoma. (27594424)
2017
15
ZFP36L2 promotes cancer cell aggressiveness and is regulated by antitumor microRNA-375 in pancreatic ductal adenocarcinoma. (27862697)
2017
16
Histologic Tumor Grade and Preoperative Bilary Drainage are the Unique Independent Prognostic Factors of Survival in Pancreatic Ductal Adenocarcinoma Patients After Pancreaticoduodenectomy. (28059940)
2017
17
Multicenter Phase II Study of Intravenous and Intraperitoneal Paclitaxel With S-1 for Pancreatic Ductal Adenocarcinoma Patients With Peritoneal Metastasis. (28059968)
2017
18
Retraction notice to candidate agents for pancreatic ductal adenocarcinoma identified by a sub-pathway based method [GENE 540/2 (2014) 232-7]. (27195335)
2016
19
Circular RNA Expression Profile of Pancreatic Ductal Adenocarcinoma Revealed by Microarray. (27997903)
2016
20
Clinical significance of serum Wisteria floribunda agglutinin-positive Mac-2 binding protein in pancreatic ductal adenocarcinoma. (27665173)
2016
21
Analysis of long non-coding RNA expression profiles in pancreatic ductal adenocarcinoma. (27628540)
2016
22
dCK Expression and Gene Polymorphism With Gemcitabine Chemosensitivity in Patients With Pancreatic Ductal Adenocarcinoma: A Strobe-Compliant Observational Study. (26962792)
2016
23
TH-EF-BRA-04: Individually Optimized Contrast-Enhanced 4D-CT for Radiotherapy Simulation in Pancreatic Ductal Adenocarcinoma. (28048183)
2016
24
In silico analysis of the transportome in human pancreatic ductal adenocarcinoma. (27652669)
2016
25
The Results of Pancreatic Resections and Long-Term Survival for Pancreatic Ductal Adenocarcinoma: A Single-Institution Experience. (27130378)
2016
26
CLIC1 overexpression is associated with poor prognosis in pancreatic ductal adenocarcinomas. (27461670)
2016
27
HDAC2 promotes loss of primary cilia in pancreatic ductal adenocarcinoma. (28028031)
2016
28
Validation of a Proposed Tumor Regression Grading Scheme for Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy as a Prognostic Indicator for Survival. (27631521)
2016
29
Monocarboxylate Transporters MCT1 and MCT4 Regulate Migration and Invasion of Pancreatic Ductal Adenocarcinoma Cells. (26765963)
2016
30
Overexpression of SOX18 correlates with accelerated cell growth and poor prognosis in human pancreatic ductal adenocarcinoma. (27663663)
2016
31
Procathepsin E is highly abundant but minimally active in pancreatic ductal adenocarcinoma tumors. (27149201)
2016
32
FOXC2 is up-regulated in pancreatic ductal adenocarcinoma and promotes the growth and migration of cancer cells. (26733175)
2016
33
SOX2 functions as a molecular rheostat to control the growth, tumorigenicity and drug responses of pancreatic ductal adenocarcinoma cells. (27145457)
2016
34
Comparison of ILK and ERP29 expressions in benign and malignant pancreatic lesions and their clinicopathological significances in pancreatic ductal adenocarcinomas. (26887611)
2016
35
Characterization of KRAS Mutation in Acinar and Langerhans Islet Cells of Patients With Pancreatic Ductal Adenocarcinoma. (26474433)
2016
36
SERPINB5 Promoter Hypomethylation Differentiates Pancreatic Ductal Adenocarcinoma From Pancreatitis. (26646275)
2016
37
High-Level Expression and Prognostic Significance of Matrix Metalloprotease-19 and Matrix Metalloprotease-20 in Human Pancreatic Ductal Adenocarcinoma. (26692439)
2016
38
Assessment of different 3D culture systems to study tumor phenotype and chemosensitivity in pancreatic ductal adenocarcinoma. (27177201)
2016
39
MiR-221 Promotes Capan-2 Pancreatic Ductal Adenocarcinoma Cells Proliferation by Targeting PTEN-Akt. (27230035)
2016
40
Identification of Novel Serum Autoantibodies for Differential Diagnosis of Autoimmune Pancreatitis and Pancreatic Ductal Adenocarcinoma. (27623556)
2016
41
Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: A retrospective cohort study. (27178104)
2016
42
Epithelial-to-mesenchymal transition in pancreatic ductal adenocarcinoma: Characterization in a 3D-cell culture model. (27182158)
2016
43
Intratumor Heterogeneity of KRAS Mutation Status in Pancreatic Ductal Adenocarcinoma Is Associated With Smaller Lesions. (26646269)
2016
44
Glypican-3 and KRT19 are markers associating with metastasis and poor prognosis of pancreatic ductal adenocarcinoma. (27689616)
2016
45
ROCK signaling promotes collagen remodeling to facilitate invasive pancreatic ductal adenocarcinoma tumor cell growth. (28031255)
2016
46
RASSF1 tumor suppressor gene in pancreatic ductal adenocarcinoma: correlation of expression, chromosomal status and epigenetic changes. (26754001)
2016
47
Hes1 Controls Exocrine Cell Plasticity and Restricts Development of Pancreatic Ductal Adenocarcinoma in a Mouse Model. (27639167)
2016
48
Immunohistochemical Markers Distinguishing Cholangiocellular Carcinoma (CCC) from Pancreatic Ductal Adenocarcinoma (PDAC) Discovered by Proteomic Analysis of Microdissected Cells. (26644413)
2016
49
C1qTNF related protein 4 (CTRP4) promotes pancreatic ductal adenocarcinoma cell proliferation and migration via activation of EGFR-PI3K-NF-I_B pathway. (27641756)
2016
50
MicroRNA-506 is up-regulated in the development of pancreatic ductal adenocarcinoma and is associated with attenuated disease progression. (27371108)
2016

Variations for Pancreatic Ductal Adenocarcinoma

About this section

Copy number variations for Pancreatic Ductal Adenocarcinoma from CNVD:

6 (show top 50)    (show all 315)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1146161109662726110421733LossPancreatic ductal adenocarcinoma
2149791111694621112653686LossPancreatic ductal adenocarcinoma
31514111129689511700048LossPancreatic ductal adenocarcinoma
4152541113902673114772618LossPancreatic ductal adenocarcinoma
5210711156591077157602759GainPancreatic ductal adenocarcinoma
62292711699096217780550LossPancreatic ductal adenocarcinoma
7236651172632928173462394GainPancreatic ductal adenocarcinoma
8239831174098656174792564GainPancreatic ductal adenocarcinoma
92426811778055018767187LossPancreatic ductal adenocarcinoma
102534011876718719870518LossPancreatic ductal adenocarcinoma
11254291189012940189640525GainPancreatic ductal adenocarcinoma
12255251190940606191897513GainPancreatic ductal adenocarcinoma
13256031191897513192833019GainPancreatic ductal adenocarcinoma
14256681192833019193928417GainPancreatic ductal adenocarcinoma
15259571195125528196179631GainPancreatic ductal adenocarcinoma
16261231197274194198251428GainPancreatic ductal adenocarcinoma
172628611987051821264484LossPancreatic ductal adenocarcinoma
18276491210637543211466127GainPancreatic ductal adenocarcinoma
19295121232834654234059648GainPancreatic ductal adenocarcinoma
202998812388148224596143LossPancreatic ductal adenocarcinoma
213078312459614324901021LossPancreatic ductal adenocarcinoma
223104912490102126202341LossPancreatic ductal adenocarcinoma
233122912620234127453508LossPancreatic ductal adenocarcinoma
243147512770297428279739LossPancreatic ductal adenocarcinoma
253164912915441829949616LossPancreatic ductal adenocarcinoma
263171012994961631202941LossPancreatic ductal adenocarcinoma
273182213120294132179980LossPancreatic ductal adenocarcinoma
283210413358173034569385LossPancreatic ductal adenocarcinoma
293221113456938535804738LossPancreatic ductal adenocarcinoma
303249813695373237599763LossPancreatic ductal adenocarcinoma
313264913814371738830556LossPancreatic ductal adenocarcinoma
3232759139136335229374LossPancreatic ductal adenocarcinoma
333329714426866745000776LossPancreatic ductal adenocarcinoma
343374514753287248556325LossPancreatic ductal adenocarcinoma
3534094152293746509870LossPancreatic ductal adenocarcinoma
363419915337144053750907LossPancreatic ductal adenocarcinoma
373423015375090754788971LossPancreatic ductal adenocarcinoma
3836948183793889142502LossPancreatic ductal adenocarcinoma
3937455191425029661749LossPancreatic ductal adenocarcinoma
403850810103075332103271952GainPancreatic ductal adenocarcinoma
4141307101591759317007248GainPancreatic ductal adenocarcinoma
4241728102285421023744923GainPancreatic ductal adenocarcinoma
4344446105720376058367659GainPancreatic ductal adenocarcinoma
4444911106484628166342495GainPancreatic ductal adenocarcinoma
4545553107214331273316160LossPancreatic ductal adenocarcinoma
4645655107331616074391172GainPancreatic ductal adenocarcinoma
4745775107439117275333936GainPancreatic ductal adenocarcinoma
4845937107533393676299818GainPancreatic ductal adenocarcinoma
4946231107927396180171344LossPancreatic ductal adenocarcinoma
5046288108017134481279277LossPancreatic ductal adenocarcinoma

Expression for genes affiliated with Pancreatic Ductal Adenocarcinoma

About this section
LifeMap Discovery
Genes differentially expressed in tissues of Pancreatic Ductal Adenocarcinoma patients vs. healthy controls: 35 (show all 375)
id Gene Description Tissue Up/Dn Fold Change (log2) P value
1SYCNsyncollinPancreas-8.040.000
2GP2glycoprotein 2 (zymogen granule membrane)Pancreas-7.990.000
3ALBalbuminPancreas-7.950.000
4SERPINI2serpin peptidase inhibitor, clade I (pancpin), member 2Pancreas-7.950.000
5CELA2Bchymotrypsin-like elastase family, member 2BPancreas-7.740.000
6PNLIPRP1pancreatic lipase-related protein 1Pancreas-7.660.000
7PDIA2protein disulfide isomerase family A, member 2Pancreas-7.530.000
8SPXspexin hormonePancreas-7.530.000
9CTRLchymotrypsin-likePancreas-7.520.000
10COL10A1collagen, type X, alpha 1Pancreas+7.520.000
11CELPcarboxyl ester lipase pseudogenePancreas-7.500.000
12COL5A1collagen, type V, alpha 1Pancreas+7.460.000
13SULF1sulfatase 1Pancreas+7.380.000
14CUZD1CUB and zona pellucida-like domains 1Pancreas-7.290.000
15POSTNperiostin, osteoblast specific factorPancreas+7.240.000
16COL1A1collagen, type I, alpha 1Pancreas+7.170.000
17AQP8aquaporin 8Pancreas-7.140.000
18CEACAM5carcinoembryonic antigen-related cell adhesion molecule 5Pancreas+7.100.000
19COL11A1collagen, type XI, alpha 1Pancreas+7.000.000
20CLPScolipase, pancreaticPancreas-6.990.000
21INHBAinhibin, beta APancreas+6.950.000
22CPA2carboxypeptidase A2 (pancreatic)Pancreas-6.880.000
23CTRCchymotrypsin C (caldecrin)Pancreas-6.870.000
24CEACAM6carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross reacting antigen)Pancreas+6.860.000
25PLA2G1Bphospholipase A2, group IB (pancreas)Pancreas-6.790.001
26COL3A1collagen, type III, alpha 1Pancreas+6.780.000
27SFRP4secreted frizzled-related protein 4Pancreas+6.760.000
28CELA3Achymotrypsin-like elastase family, member 3APancreas-6.760.001
29GNMTglycine N-methyltransferasePancreas-6.740.000
30COL1A2collagen, type I, alpha 2Pancreas+6.720.000
31REG1Pregenerating islet-derived 1 pseudogenePancreas-6.710.000
32S100PS100 calcium binding protein PPancreas+6.670.000
33CELA3Bchymotrypsin-like elastase family, member 3BPancreas-6.660.001
34CELcarboxyl ester lipasePancreas-6.630.001
35CTHRC1collagen triple helix repeat containing 1Pancreas+6.600.000
36CPA1carboxypeptidase A1 (pancreatic)Pancreas-6.560.001
37VCANversicanPancreas+6.510.000
38TMEM52transmembrane protein 52Pancreas-6.400.000
39REG1Bregenerating islet-derived 1 betaPancreas-6.350.002
40CTSEcathepsin EPancreas+6.300.000
41GLS2glutaminase 2 (liver, mitochondrial)Pancreas-6.280.000
42KLK1kallikrein 1Pancreas-6.260.000
43GJB2gap junction protein, beta 2, 26kDaPancreas+6.240.000
44REG3Gregenerating islet-derived 3 gammaPancreas-6.170.000
45PLAUplasminogen activator, urokinasePancreas+6.150.000
46COL5A2collagen, type V, alpha 2Pancreas+6.130.000
47SLC39A5solute carrier family 39 (zinc transporter), member 5Pancreas-6.090.000
48ERP27endoplasmic reticulum protein 27Pancreas-6.070.000
49SEMA3Csema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3CPancreas+6.000.000
50PNLIPpancreatic lipasePancreas-5.940.004
51CXCL5chemokine (C-X-C motif) ligand 5Pancreas+5.920.000
52CBScystathionine-beta-synthasePancreas-5.850.000
53CLDN18claudin 18Pancreas+5.790.001
54PNLIPRP2pancreatic lipase-related protein 2Pancreas-5.790.003
55PM20D1peptidase M20 domain containing 1Pancreas-5.760.000
56FGL1fibrinogen-like 1Pancreas-5.720.000
57XAF1XIAP associated factor 1Pancreas+5.720.000
58NTMneurotriminPancreas+5.710.000
59PAIP2Bpoly(A) binding protein interacting protein 2BPancreas-5.700.000
60CDH11cadherin 11, type 2, OB-cadherin (osteoblast)Pancreas+5.670.000
61SAMSN1SAM domain, SH3 domain and nuclear localization signals 1Pancreas+5.660.000
62SFNstratifinPancreas+5.650.000
63MFAP5microfibrillar associated protein 5Pancreas+5.650.000
64SLC1A2solute carrier family 1 (glial high affinity glutamate transporter), member 2Pancreas-5.610.000
65TEX11testis expressed 11Pancreas-5.570.000
66TMED6transmembrane p24 trafficking protein 6Pancreas-5.560.000
67EDNRAendothelin receptor type APancreas+5.550.000
68ASPNasporinPancreas+5.530.000
69BNIP3BCL2/adenovirus E1B 19kDa interacting protein 3Pancreas-5.450.000
70RUNX2runt-related transcription factor 2Pancreas+5.450.000
71SERPINE1serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1Pancreas+5.420.000
72LEF1lymphoid enhancer-binding factor 1Pancreas+5.410.000
73COL12A1collagen, type XII, alpha 1Pancreas+5.410.000
74PCDH7protocadherin 7Pancreas+5.390.000
75IFI44Linterferon-induced protein 44-likePancreas+5.380.000
76FAPfibroblast activation protein, alphaPancreas+5.380.000
77LY75lymphocyte antigen 75Pancreas+5.380.000
78PTPRCprotein tyrosine phosphatase, receptor type, CPancreas+5.360.000
79SFRP2secreted frizzled-related protein 2Pancreas+5.360.000
80CPB1carboxypeptidase B1 (tissue)Pancreas-5.340.006
81AKR7A3aldo-keto reductase family 7, member A3 (aflatoxin aldehyde reductase)Pancreas-5.300.000
82REG3Aregenerating islet-derived 3 alphaPancreas-5.300.009
83CTRB2chymotrypsinogen B2Pancreas-5.290.005
84GBP1guanylate binding protein 1, interferon-induciblePancreas+5.280.000
85PRSS1protease, serine, 1 (trypsin 1)Pancreas-5.260.007
86GREM1gremlin 1, DAN family BMP antagonistPancreas+5.220.000
87SYBUsyntabulin (syntaxin-interacting)Pancreas-5.210.000
88THY1Thy-1 cell surface antigenPancreas+5.210.000
89VNN1vanin 1Pancreas+5.200.000
90FNDC1fibronectin type III domain containing 1Pancreas+5.170.000
91HEPHhephaestinPancreas+5.160.000
92SLC6A14solute carrier family 6 (amino acid transporter), member 14Pancreas+5.150.000
93RBPJLrecombination signal binding protein for immunoglobulin kappa J region-likePancreas-5.140.000
94KLF5Kruppel-like factor 5 (intestinal)Pancreas+5.120.000
95TRIM29tripartite motif containing 29Pancreas+5.110.000
96PRSS3protease, serine, 3Pancreas-5.110.000
97CA4carbonic anhydrase IVPancreas-5.100.000
98SLC20A1solute carrier family 20 (phosphate transporter), member 1Pancreas+5.100.000
99PLAC8placenta-specific 8Pancreas+5.090.000
100MMP12matrix metallopeptidase 12Pancreas+5.060.000
101AADACarylacetamide deacetylasePancreas-5.040.000
102MGPmatrix Gla proteinPancreas+5.020.000
103MMP11matrix metallopeptidase 11Pancreas+5.000.000
104EPB41L4Berythrocyte membrane protein band 4.1 like 4BPancreas-4.990.000
105KYNUkynureninasePancreas+4.970.000
106OLFML2Bolfactomedin-like 2BPancreas+4.970.000
107SLC4A4solute carrier family 4 (sodium bicarbonate cotransporter), member 4Pancreas-4.970.000
108HOPXHOP homeoboxPancreas+4.960.000
109DUOX2dual oxidase 2Pancreas+4.960.000
110CALD1caldesmon 1Pancreas+4.950.000
111TNFAIP6tumor necrosis factor, alpha-induced protein 6Pancreas+4.950.000
112AZGP1alpha-2-glycoprotein 1, zinc-bindingPancreas-4.940.000
113TMPRSS4transmembrane protease, serine 4Pancreas+4.930.000
114HS3ST1heparan sulfate (glucosamine) 3-O-sulfotransferase 1Pancreas+4.930.000
115SLC30A2solute carrier family 30 (zinc transporter), member 2Pancreas-4.930.000
116ANO1anoctamin 1, calcium activated chloride channelPancreas+4.920.000
117CSTAcystatin A (stefin A)Pancreas+4.900.000
118AOX1aldehyde oxidase 1Pancreas-4.900.000
119ECT2epithelial cell transforming 2Pancreas+4.880.000
120KPNA2karyopherin alpha 2 (RAG cohort 1, importin alpha 1)Pancreas+4.880.000
121BACE1beta-site APP-cleaving enzyme 1Pancreas-4.870.000
122CYP1B1cytochrome P450, family 1, subfamily B, polypeptide 1Pancreas+4.870.000
123TMEM97transmembrane protein 97Pancreas-4.870.000
124CXCL14chemokine (C-X-C motif) ligand 14Pancreas+4.860.000
125IL22RA1interleukin 22 receptor, alpha 1Pancreas-4.860.000
126HMCN1hemicentin 1Pancreas+4.850.000
127CXCR4chemokine (C-X-C motif) receptor 4Pancreas+4.850.000
128MMP1matrix metallopeptidase 1Pancreas+4.850.001
129GAMTguanidinoacetate N-methyltransferasePancreas-4.840.000
130BCL2A1BCL2-related protein A1Pancreas+4.830.000
131TRHDEthyrotropin-releasing hormone degrading enzymePancreas-4.830.000
132GCNT3glucosaminyl (N-acetyl) transferase 3, mucin typePancreas+4.820.000
133CCKBRcholecystokinin B receptorPancreas-4.820.000
134AREGamphiregulinPancreas+4.820.000
135ZNF207zinc finger protein 207Pancreas+4.810.000
136SLC6A6solute carrier family 6 (neurotransmitter transporter), member 6Pancreas+4.810.000
137SPARCsecreted protein, acidic, cysteine-rich (osteonectin)Pancreas+4.800.000
138GABRPgamma-aminobutyric acid (GABA) A receptor, piPancreas+4.790.001
139HOMER2homer scaffolding protein 2Pancreas-4.790.000
140IFI44interferon-induced protein 44Pancreas+4.790.000
141PHLDA1pleckstrin homology-like domain, family A, member 1Pancreas+4.790.000
142SLC43A1solute carrier family 43 (amino acid system L transporter), member 1Pancreas-4.780.000
143HLA-DPA1major histocompatibility complex, class II, DP alpha 1Pancreas+4.780.000
144SEL1Lsel-1 suppressor of lin-12-like (C. elegans)Pancreas-4.780.000
145PELI1pellino E3 ubiquitin protein ligase 1Pancreas+4.770.000
146ITGA2integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor)Pancreas+4.770.000
147STAT1signal transducer and activator of transcription 1, 91kDaPancreas+4.770.000
148TPSB2tryptase beta 2 (gene/pseudogene)Pancreas+4.760.000
149LAMA4laminin, alpha 4Pancreas+4.760.000
150LINC00339long intergenic non-protein coding RNA 339Pancreas-4.760.000
151HLA-DQB1major histocompatibility complex, class II, DQ beta 1Pancreas+4.760.000
152RGS1regulator of G-protein signaling 1Pancreas+4.730.000
153ITGBL1integrin, beta-like 1 (with EGF-like repeat domains)Pancreas+4.720.000
154ALDOBaldolase B, fructose-bisphosphatePancreas-4.720.000
155CCL18chemokine (C-C motif) ligand 18 (pulmonary and activation-regulated)Pancreas+4.720.000
156KRT19keratin 19, type IPancreas+4.710.000
157NREPneuronal regeneration related proteinPancreas+4.700.000
158SYTL2synaptotagmin-like 2Pancreas+4.700.000
159NQO1NAD(P)H dehydrogenase, quinone 1Pancreas+4.690.000
160GPX2glutathione peroxidase 2Pancreas+4.690.001
161GPNMBglycoprotein (transmembrane) nmbPancreas+4.690.000
162ITGB6integrin, beta 6Pancreas+4.670.000
163HPGDhydroxyprostaglandin dehydrogenase 15-(NAD)Pancreas+4.670.000
164TNFSF13Btumor necrosis factor (ligand) superfamily, member 13bPancreas+4.660.000
165MPEG1macrophage expressed 1Pancreas+4.660.000
166LAMC2laminin, gamma 2Pancreas+4.660.000
167CCL20chemokine (C-C motif) ligand 20Pancreas+4.660.000
168ZEB2zinc finger E-box binding homeobox 2Pancreas+4.660.000
169LAMA3laminin, alpha 3Pancreas+4.630.000
170JMJD1Cjumonji domain containing 1CPancreas+4.630.000
171DEFB1defensin, beta 1Pancreas-4.630.000
172EPSTI1epithelial stromal interaction 1 (breast)Pancreas+4.620.000
173CD109CD109 moleculePancreas+4.610.000
174LCP2lymphocyte cytosolic protein 2 (SH2 domain containing leukocyte protein of 76kDa)Pancreas+4.590.000
175ARSEarylsulfatase E (chondrodysplasia punctata 1)Pancreas-4.580.000
176CTSKcathepsin KPancreas+4.570.000
177CD52CD52 moleculePancreas+4.570.000
178REG1Aregenerating islet-derived 1 alphaPancreas-4.560.016
179TGFBR1transforming growth factor, beta receptor 1Pancreas+4.550.000
180CASP1caspase 1, apoptosis-related cysteine peptidasePancreas+4.550.000
181CCDC80coiled-coil domain containing 80Pancreas+4.550.000
182CST1cystatin SNPancreas+4.530.000
183FBN1fibrillin 1Pancreas+4.520.000
184DPEP1dipeptidase 1 (renal)Pancreas-4.500.000
185GPR183G protein-coupled receptor 183Pancreas+4.500.000
186IGLimmunoglobulin lambda locusPancreas+4.490.000
187PTGS2prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase)Pancreas+4.490.001
188GLT8D2glycosyltransferase 8 domain containing 2Pancreas+4.460.000
189EGR2early growth response 2Pancreas+4.460.000
190KLK10kallikrein-related peptidase 10Pancreas+4.440.002
191THBS2thrombospondin 2Pancreas+4.440.000
192CAPN8calpain 8Pancreas+4.430.000
193NR5A2nuclear receptor subfamily 5, group A, member 2Pancreas-4.430.000
194PDLIM3PDZ and LIM domain 3Pancreas+4.430.000
195ANTXR1anthrax toxin receptor 1Pancreas+4.420.000
196ANPEPalanyl (membrane) aminopeptidasePancreas-4.420.002
197ADCY7adenylate cyclase 7Pancreas+4.410.000
198OAS12'-5'-oligoadenylate synthetase 1, 40/46kDaPancreas+4.400.000
199PDK4pyruvate dehydrogenase kinase, isozyme 4Pancreas-4.390.000
200COCHcochlinPancreas-4.380.000
201GUCA1Cguanylate cyclase activator 1CPancreas-4.380.000
202P2RX1purinergic receptor P2X, ligand gated ion channel, 1Pancreas-4.370.000
203FAM26Ffamily with sequence similarity 26, member FPancreas+4.370.000
204TAGAPT-cell activation RhoGTPase activating proteinPancreas+4.360.000
205IGKV4-1immunoglobulin kappa variable 4-1Pancreas+4.360.000
206PRDM1PR domain containing 1, with ZNF domainPancreas+4.360.000
207EVI2Becotropic viral integration site 2BPancreas+4.350.000
208LOC284454uncharacterized LOC284454Pancreas+4.340.000
209C5complement component 5Pancreas-4.340.000
210TRIM14tripartite motif containing 14Pancreas+4.340.000
211CEMIPcell migration inducing protein, hyaluronan bindingPancreas+4.330.000
212OSBPL3oxysterol binding protein-like 3Pancreas+4.330.000
213KIAA1324KIAA1324Pancreas-4.320.000
214HNRNPU-AS1HNRNPU antisense RNA 1Pancreas+4.320.000
215GPR34G protein-coupled receptor 34Pancreas+4.310.000
216ERO1Bendoplasmic reticulum oxidoreductase betaPancreas-4.310.000
217CXCL8chemokine (C-X-C motif) ligand 8Pancreas+4.300.000
218C19orf33chromosome 19 open reading frame 33Pancreas+4.300.000
219C15orf48chromosome 15 open reading frame 48Pancreas+4.300.000
220CDKN2Bcyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4)Pancreas+4.290.000
221IL18interleukin 18Pancreas+4.290.000
222IGFBP3insulin-like growth factor binding protein 3Pancreas+4.290.001
223NOX4NADPH oxidase 4Pancreas+4.290.000
224KCNJ16potassium channel, inwardly rectifying subfamily J, member 16Pancreas-4.290.000
225SERPINB5serpin peptidase inhibitor, clade B (ovalbumin), member 5Pancreas+4.280.000
226IL1RNinterleukin 1 receptor antagonistPancreas+4.280.000
227GPR137BG protein-coupled receptor 137BPancreas+4.280.000
228CA12carbonic anhydrase XIIPancreas-4.280.000
229FPR3formyl peptide receptor 3Pancreas+4.270.000
230HSPA6heat shock 70kDa protein 6 (HSP70B')Pancreas+4.270.000
231RUNX1runt-related transcription factor 1Pancreas+4.270.000
232DPY19L1dpy-19-like 1 (C. elegans)Pancreas+4.270.000
233HPNhepsinPancreas-4.270.000
234CD69CD69 moleculePancreas+4.260.000
235GBP3guanylate binding protein 3Pancreas+4.250.000
236CXCL3chemokine (C-X-C motif) ligand 3Pancreas+4.240.000
237COA1cytochrome c oxidase assembly factor 1 homologPancreas+4.240.000
238NCF2neutrophil cytosolic factor 2Pancreas+4.240.000
239DLEU2deleted in lymphocytic leukemia 2 (non-protein coding)Pancreas+4.240.000
240LAMB3laminin, beta 3Pancreas+4.240.000
241ADAM28ADAM metallopeptidase domain 28Pancreas+4.230.000
242PSAT1phosphoserine aminotransferase 1Pancreas-4.230.000
243CHRM3cholinergic receptor, muscarinic 3Pancreas-4.220.000
244SLC38A5solute carrier family 38, member 5Pancreas-4.210.000
245OLR1oxidized low density lipoprotein (lectin-like) receptor 1Pancreas+4.210.000
246CMAHPcytidine monophospho-N-acetylneuraminic acid hydroxylase, pseudogenePancreas+4.210.000
247GPRC5AG protein-coupled receptor, class C, group 5, member APancreas+4.210.000
248AHNAK2AHNAK nucleoprotein 2Pancreas+4.200.000
249CSF2RBcolony stimulating factor 2 receptor, beta, low-affinity (granulocyte-macrophage)Pancreas+4.200.000
250OSBPL10oxysterol binding protein-like 10Pancreas+4.200.000
251SH3KBP1SH3-domain kinase binding protein 1Pancreas+4.190.000
252IL2RGinterleukin 2 receptor, gammaPancreas+4.190.000
253ACSL5acyl-CoA synthetase long-chain family member 5Pancreas+4.180.000
254KRT17keratin 17, type IPancreas+4.180.000
255IGHMimmunoglobulin heavy constant muPancreas+4.170.000
256SDR16C5short chain dehydrogenase/reductase family 16C, member 5Pancreas+4.170.001
257CD86CD86 moleculePancreas+4.170.000
258AKR1B10aldo-keto reductase family 1, member B10 (aldose reductase)Pancreas+4.170.003
259BIRC3baculoviral IAP repeat containing 3Pancreas+4.170.000
260SLC2A3solute carrier family 2 (facilitated glucose transporter), member 3Pancreas+4.170.000
261TRIOtrio Rho guanine nucleotide exchange factorPancreas+4.170.000
262TPSAB1tryptase alpha/beta 1Pancreas+4.160.000
263FAM150Bfamily with sequence similarity 150, member BPancreas-4.160.000
264GIMAP2GTPase, IMAP family member 2Pancreas+4.150.000
265PLAURplasminogen activator, urokinase receptorPancreas+4.140.000
266LOXlysyl oxidasePancreas+4.140.000
267MS4A6Amembrane-spanning 4-domains, subfamily A, member 6APancreas+4.140.000
268CTSScathepsin SPancreas+4.130.000
269PLXNC1plexin C1Pancreas+4.120.000
270PHLDA2pleckstrin homology-like domain, family A, member 2Pancreas+4.110.000
271RBP1retinol binding protein 1, cellularPancreas-4.110.000
272GZMAgranzyme A (granzyme 1, cytotoxic T-lymphocyte-associated serine esterase 3)Pancreas+4.110.000
273POU2AF1POU class 2 associating factor 1Pancreas+4.100.000
274OGNosteoglycinPancreas+4.100.000
275DKK3dickkopf WNT signaling pathway inhibitor 3Pancreas+4.100.000
276FCGR2BFc fragment of IgG, low affinity IIb, receptor (CD32)Pancreas+4.100.000
277RASGRP1RAS guanyl releasing protein 1 (calcium and DAG-regulated)Pancreas+4.090.000
278SPON1spondin 1, extracellular matrix proteinPancreas+4.080.000
279ACADLacyl-CoA dehydrogenase, long chainPancreas-4.080.000
280LOXL1lysyl oxidase-like 1Pancreas+4.080.000
281CD74CD74 molecule, major histocompatibility complex, class II invariant chainPancreas+4.070.000
282CLEC7AC-type lectin domain family 7, member APancreas+4.060.000
283REG4regenerating islet-derived family, member 4Pancreas+4.060.038
284CEACAM1carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein)Pancreas+4.060.000
285LACC1laccase (multicopper oxidoreductase) domain containing 1Pancreas+4.060.000
286UHRF1BP1LUHRF1 binding protein 1-likePancreas+4.060.000
287ALG13ALG13, UDP-N-acetylglucosaminyltransferase subunitPancreas+4.050.000
288ZBTB16zinc finger and BTB domain containing 16Pancreas-4.020.000
289SLC7A1solute carrier family 7 (cationic amino acid transporter, y+ system), member 1Pancreas-4.000.000
290H19H19, imprinted maternally expressed transcript (non-protein coding)Pancreas-3.980.010
291ITIH4inter-alpha-trypsin inhibitor heavy chain family, member 4Pancreas-3.960.000
292LGALS2lectin, galactoside-binding, soluble, 2Pancreas-3.940.001
293PRSS2protease, serine, 2 (trypsin 2)Pancreas-3.930.026
294ACSM3acyl-CoA synthetase medium-chain family member 3Pancreas-3.920.000
295KIF1Akinesin family member 1APancreas-3.920.000
296INSRinsulin receptorPancreas-3.890.000
297PDCD4programmed cell death 4 (neoplastic transformation inhibitor)Pancreas-3.880.000
298SERPINA4serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 4Pancreas-3.870.000
299C6complement component 6Pancreas-3.840.000
300KCNK3potassium channel, two pore domain subfamily K, member 3Pancreas-3.830.000
301GPT2glutamic pyruvate transaminase (alanine aminotransferase) 2Pancreas-3.810.000
302COMTD1catechol-O-methyltransferase domain containing 1Pancreas-3.810.000
303F8coagulation factor VIII, procoagulant componentPancreas-3.790.000
304PGBD5piggyBac transposable element derived 5Pancreas-3.790.000
305SFRP5secreted frizzled-related protein 5Pancreas-3.790.000
306LEFTY1left-right determination factor 1Pancreas-3.770.005
307KIRREL2kin of IRRE like 2 (Drosophila)Pancreas-3.760.000
308TM7SF2transmembrane 7 superfamily member 2Pancreas-3.760.000
309DAPL1death associated protein-like 1Pancreas-3.750.000
310IMPA2inositol(myo)-1(or 4)-monophosphatase 2Pancreas-3.750.000
311FXYD2FXYD domain containing ion transport regulator 2Pancreas-3.740.000
312PLXNA2plexin A2Pancreas-3.730.000
313NPTX2neuronal pentraxin IIPancreas-3.710.000
314SSFA2sperm specific antigen 2Pancreas-3.700.000
315SLC25A15solute carrier family 25 (mitochondrial carrier; ornithine transporter) member 15Pancreas-3.660.000
316NTRK2neurotrophic tyrosine kinase, receptor, type 2Pancreas-3.650.000
317DLK1delta-like 1 homolog (Drosophila)Pancreas-3.650.001
318FABP4fatty acid binding protein 4, adipocytePancreas-3.630.008
319LOC553137uncharacterized LOC553137Pancreas-3.610.000
320ECHDC3enoyl CoA hydratase domain containing 3Pancreas-3.610.000
321GATMglycine amidinotransferase (L-arginine:glycine amidinotransferase)Pancreas-3.600.000
322PHGDHphosphoglycerate dehydrogenasePancreas-3.580.000
323SLC7A2solute carrier family 7 (cationic amino acid transporter, y+ system), member 2Pancreas-3.560.000
324CRYBA2crystallin, beta A2Pancreas-3.560.000
325KCNJ8potassium channel, inwardly rectifying subfamily J, member 8Pancreas-3.540.000
326HSD17B8hydroxysteroid (17-beta) dehydrogenase 8Pancreas-3.530.000
327SLC1A4solute carrier family 1 (glutamate/neutral amino acid transporter), member 4Pancreas-3.520.000
328SLC39A8solute carrier family 39 (zinc transporter), member 8Pancreas-3.500.000
329FOXA3forkhead box A3Pancreas-3.460.000
330FAM3Bfamily with sequence similarity 3, member BPancreas-3.430.003
331SERPINA5serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 5Pancreas-3.420.001
332SERPINA3serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3Pancreas-3.400.007
333S100A12S100 calcium binding protein A12Pancreas-3.370.000
334C19orf48chromosome 19 open reading frame 48Pancreas-3.350.000
335SPAG4sperm associated antigen 4Pancreas-3.340.000
336PARM1prostate androgen-regulated mucin-like protein 1Pancreas-3.340.000
337RHOBTB3Rho-related BTB domain containing 3Pancreas-3.330.000
338CLDN10claudin 10Pancreas-3.300.025
339RPH3ALrabphilin 3A-like (without C2 domains)Pancreas-3.300.000
340MTUS2microtubule associated tumor suppressor candidate 2Pancreas-3.290.000
341CTNND2catenin (cadherin-associated protein), delta 2Pancreas-3.290.000
342BSPRYB-box and SPRY domain containingPancreas-3.290.000
343LINC00261long intergenic non-protein coding RNA 261Pancreas-3.290.000
344SSTsomatostatinPancreas-3.260.033
345RAB3DRAB3D, member RAS oncogene familyPancreas-3.250.000
346BTG2BTG family, member 2Pancreas-3.240.000
347NLE1notchless homolog 1 (Drosophila)Pancreas-3.230.000
348CFTRcystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7)Pancreas-3.210.016
349DCDC2doublecortin domain containing 2Pancreas-3.200.001
350ANXA9annexin A9Pancreas-3.180.000
351TPST2tyrosylprotein sulfotransferase 2Pancreas-3.170.000
352USTuronyl-2-sulfotransferasePancreas-3.170.000
353MSRB1methionine sulfoxide reductase B1Pancreas-3.170.000
354MAOAmonoamine oxidase APancreas-3.150.000
355PAK3p21 protein (Cdc42/Rac)-activated kinase 3Pancreas-3.130.000
356PDE8Bphosphodiesterase 8BPancreas-3.120.000
357TMEM125transmembrane protein 125Pancreas-3.120.000
358CLDN3claudin 3Pancreas-3.120.011
359C21orf2chromosome 21 open reading frame 2Pancreas-3.120.000
360P4HBprolyl 4-hydroxylase, beta polypeptidePancreas-3.120.000
361SLC38A4solute carrier family 38, member 4Pancreas-3.110.000
362SYTL1synaptotagmin-like 1Pancreas-3.110.000
363VEPH1ventricular zone expressed PH domain-containing 1Pancreas-3.100.000
364STXBP6syntaxin binding protein 6 (amisyn)Pancreas-3.090.000
365TPM1tropomyosin 1 (alpha)Pancreas-3.090.000
366PIFOprimary cilia formationPancreas-3.090.000
367KLHDC10kelch domain containing 10Pancreas-3.080.000
368SLC3A1solute carrier family 3 (amino acid transporter heavy chain), member 1Pancreas-3.080.034
369DHRS12dehydrogenase/reductase (SDR family) member 12Pancreas-3.080.000
370SLC37A4solute carrier family 37 (glucose-6-phosphate transporter), member 4Pancreas-3.070.000
371ARRB1arrestin, beta 1Pancreas-3.070.000
372APLP1amyloid beta (A4) precursor-like protein 1Pancreas-3.020.000
373MUC15mucin 15, cell surface associatedPancreas-3.020.000
374STC2stanniocalcin 2Pancreas-3.020.000
375BEX5brain expressed, X-linked 5Pancreas-3.010.001

Search GEO for disease gene expression data for Pancreatic Ductal Adenocarcinoma.

Pathways for genes affiliated with Pancreatic Ductal Adenocarcinoma

About this section

Pathways related to Pancreatic Ductal Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50)    (show all 94)
idSuper pathwaysScoreTop Affiliating Genes
110.0HRAS, KRAS, TP53
210.0AKT1, HRAS, KRAS
310.0AKT1, HRAS, KRAS
410.0AKT1, SMAD4, TP53
510.0EGFR, HRAS, KRAS
6
Show member pathways
10.0EGFR, HRAS, KRAS
7
Show member pathways
10.0AKT1, CDKN2A, TP53
810.0AKT1, CDH1, SMAD4
910.0CDKN2A, EGFR, TP53
1010.0AKT1, EGFR, HRAS
11
Show member pathways
10.0AKT1, EGFR, TP53
12
Show member pathways
10.0CTNNB1, HRAS, SMAD4
1310.0AKT1, CDH1, EGFR
149.9ERBB2, HRAS, SMAD4
159.9CTNNB1, EGFR, TP53
169.9AKT1, CDH1, CTNNB1
179.9CDH1, CTNNB1, EGFR
189.9AKT1, HRAS, KRAS, SMAD4
199.9CDKN2A, HRAS, KRAS, TP53
209.9CDKN2A, HRAS, SMAD4, TP53
219.9AKT1, HRAS, KRAS, TP53
22
Show member pathways
9.9AKT1, HRAS, KRAS, TP53
23
Show member pathways
9.9AKT1, HRAS, KRAS, TP53
24
Show member pathways
9.9AKT1, HRAS, KRAS, TP53
25
Show member pathways
9.9AKT1, HRAS, KRAS, TP53
269.9AKT1, HRAS, KRAS, TP53
279.9EGFR, HRAS, KRAS, TP53
28
Show member pathways
9.9AKT1, CDKN2A, KRAS, TP53
29
Show member pathways
9.9CDH1, CDKN2A, SMAD4, TP53
30
Show member pathways
9.8AKT1, EGFR, HRAS, KRAS
31
Show member pathways
9.8AKT1, EGFR, HRAS, KRAS
32
Show member pathways
9.8AKT1, EGFR, HRAS, KRAS
339.8CDKN2A, CTNNB1, SMAD4, TP53
34
Show member pathways
9.8EGFR, ERBB2, HRAS, KRAS
359.8EGFR, ERBB2, HRAS, KRAS
369.8AKT1, ERBB2, HRAS, TP53
379.8AKT1, CTNNB1, EGFR, SMAD4
389.8AKT1, CDKN2A, ERBB2, TP53
39
Show member pathways
9.7AKT1, EGFR, ERBB2, HRAS
40
Show member pathways
9.7AKT1, EGFR, ERBB2, TP53
419.7AKT1, CDH1, HRAS, KRAS, SMAD4
42
Show member pathways
9.7AKT1, EGFR, HRAS, KRAS, SMAD4
43
Show member pathways
9.7AKT1, EGFR, HRAS, KRAS, TP53
449.7AKT1, EGFR, HRAS, KRAS, TP53
459.7AKT1, EGFR, HRAS, KRAS, TP53
46
Show member pathways
9.7AKT1, EGFR, HRAS, KRAS, TP53
479.7AKT1, CTNNB1, EGFR, ERBB2
489.7AKT1, CTNNB1, HRAS, KRAS, SMAD4
499.6CTNNB1, GLI1, PROM1, SMAD4
50
Show member pathways
9.6AKT1, CTNNB1, HRAS, KRAS, TP53

GO Terms for genes affiliated with Pancreatic Ductal Adenocarcinoma

About this section

Cellular components related to Pancreatic Ductal Adenocarcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1catenin complexGO:001634210.6CDH1, CTNNB1
2flotillin complexGO:001660010.6CDH1, CTNNB1
3basolateral plasma membraneGO:001632310.2CTNNB1, EGFR, ERBB2, SLC29A1
4apical plasma membraneGO:001632410.1EGFR, ERBB2, MUC1, PROM1, SLC29A1
5vesicleGO:00319829.7AKT1, MUC1, MUC4, PROM1

Biological processes related to Pancreatic Ductal Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 27)
idNameGO IDScoreTop Affiliating Genes
1positive regulation of cellular senescenceGO:200077410.9CDKN2A, KRAS
2positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycleGO:003165910.9AKT1, EGFR
3cellular response to indole-3-methanolGO:007168110.9CDH1, CTNNB1
4negative regulation of immature T cell proliferation in thymusGO:003308810.8CDKN2A, ERBB2
5epidermal growth factor receptor signaling pathwayGO:000717310.8EGFR, HRAS, KRAS
6response to isolation stressGO:003590010.7HRAS, KRAS
7response to UV-AGO:007014110.7AKT1, EGFR
8cellular response to epidermal growth factor stimulusGO:007136410.7AKT1, EGFR, ERBB2
9positive regulation of epithelial cell proliferationGO:005067910.7EGFR, ERBB2, HRAS
10positive regulation of DNA replicationGO:004574010.7EGFR, GLI1, HRAS
11retina morphogenesis in camera-type eyeGO:006004210.6PROM1, PTF1A
12ERBB2 signaling pathwayGO:003812810.6EGFR, ERBB2, HRAS, KRAS
13pancreas developmentGO:003101610.5CTNNB1, MSLN, PTF1A
14positive regulation of MAP kinase activityGO:004340610.5EGFR, ERBB2, HRAS, KRAS
15phosphatidylinositol-mediated signalingGO:004801510.5AKT1, EGFR, ERBB2, TP53
16Ras protein signal transductionGO:000726510.5CDKN2A, HRAS, KRAS, TP53
17regulation of phosphatidylinositol 3-kinase signalingGO:001406610.4AKT1, EGFR, ERBB2
18cellular response to growth factor stimulusGO:007136310.4AKT1, CTNNB1, EGFR, ERBB2
19negative regulation of cell proliferationGO:000828510.4CDKN2A, CTNNB1, HRAS, SMAD4, TP53
20positive regulation of protein phosphorylationGO:000193410.3AKT1, EGFR, ERBB2, HRAS, KRAS
21positive regulation of gene expressionGO:001062810.3CTNNB1, ERBB2, HRAS, KRAS, TP53
22positive regulation of apoptotic processGO:004306510.2AKT1, CDKN2A, CTNNB1, NUPR1, TP53
23positive regulation of cell proliferationGO:000828410.0CTNNB1, EGFR, GLI1, HRAS, KRAS, SLC35F6
24cell proliferationGO:000828310.0AKT1, CTNNB1, EGFR, ERBB2, HRAS, SMAD4
25stimulatory C-type lectin receptor signaling pathwayGO:00022239.8HRAS, KRAS, MUC1, MUC4
26positive regulation of transcription from RNA polymerase II promoterGO:00459449.5AKT1, CDKN2A, CTNNB1, EGFR, GLI1, HRAS
27positive regulation of transcription, DNA-templatedGO:00458939.4AKT1, CDH1, CDKN2A, CTNNB1, EGFR, GLI1

Molecular functions related to Pancreatic Ductal Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 9)
idNameGO IDScoreTop Affiliating Genes
1nitric-oxide synthase regulator activityGO:003023510.8AKT1, EGFR
2I-SMAD bindingGO:007041110.8CTNNB1, SMAD4
3signal transducer, downstream of receptor, with protein tyrosine kinase activityGO:000471610.7EGFR, ERBB2
4RNA polymerase II transcription factor bindingGO:000108510.6CTNNB1, SMAD4, TP53
5nucleotide bindingGO:000016610.3AKT1, EGFR, ERBB2, HRAS, KRAS
6protein phosphatase bindingGO:001990310.3CTNNB1, EGFR, ERBB2, TP53
7protein kinase bindingGO:001990110.2AKT1, CDKN2A, CTNNB1, EGFR, TP53
8chromatin bindingGO:00036829.7CTNNB1, EGFR, GLI1, NUPR1, PTF1A, SMAD4
9transcription regulatory region DNA bindingGO:00442129.7CTNNB1, GLI1, SMAD4, TP53

Sources for Pancreatic Ductal Adenocarcinoma

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet